학술논문
Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept--A Retrospective Cohort Study
Document Type
Clinical report
Author
Source
Clinical Ophthalmology. February, 2020, p533, 9 p.
Subject
Language
English
ISSN
1177-5483
Abstract
Purpose: To assess visual and anatomical outcomes of intravitreal aflibercept for clinically significant diabetic macular oedema (DME). Methods: For this retrospective single-center cohort study at a tertiary referral center, we performed a data warehouse query to identify 117 treatment-naive patients (139 eyes) undergoing intravitreal treatment with aflibercept for DME between January 2014 and May 2018. Changes in best-corrected visual acuity (BCVA) values (as measured with ETDRS letters), central retinal thickness (CRT) and total macular volume (TVOL) are reported over a two-year period at various time-points. Results: The total number of injections per study eye was 5.5 [+ or -] 1.4 after one and 8.7 [+ or -] 2.2 injections after two years. Baseline visual acuity (VA) was 60.1 [+ or -] 14.5 letters. A gain of 4.8 and 9.2 letters from baseline was observed after one and two years, respectively (both p [less than or equal to] 0.01). In comparison to the mean CRT at baseline (419 [+ or -] 174 [micro]m), a CRT decrease was observed after one and two years of treatment (298 [+ or -] 115 [micro]m and 319 [+ or -] 119 [micro]m, respectively; both p [less than or equal to] 0.01). Similarly, TVOL decreased from 10.12 [+ or -] 2.05 [mm.sup.3] to 8.96 [+ or -] 0.96 [mm.sup.3] and 9.01 [+ or -] 1.29 [mm.sup.3] (both p [less than or equal to] 0.01). Conclusion: This study demonstrates that treating DME with intravitreal aflibercept yields positive functional and structural outcomes over a two-year period. However, we observed fewer injection numbers, along with inferior VA and structural outcomes than has been reported in randomized clinical trials. Our results show similar results as in patients treated with ranibizumab due to DME in real-life settings. Keywords: aflibercept, diabetic macular oedema, visual acuity, central retinal thickness
Introduction In clinical settings, the frequency of anti--VEGF injections for diabetic macular oedema (DME) is less than in landmark studies. (1-3) In light of this, there is increasing controversy regarding [...]
Introduction In clinical settings, the frequency of anti--VEGF injections for diabetic macular oedema (DME) is less than in landmark studies. (1-3) In light of this, there is increasing controversy regarding [...]